The U.S. Food and Drug Administration approved the withdrawal of opioids addiction in adults. Also, the organization claimed that it will help to overcome the barriers and help to consumers to stop using these drugs and to start new non-opioid drugs.
FDA specified that Lucemyra is the approved drug for withdrawal of the symptoms to facilitate unexpected termination of use of opioids mainly in adults and in teenagers. The organization has approved the dosage of the drugs for maximum 14 days. However, the medication will take some time to withdraw drugs action totally.
Lucemyra is not the perfect drug for withdrawal of opioid addiction or opioid use disorder (OUD), but its long-term consumption can aid the OUD. Opioid addiction was spreading; it was considered as the health crisis. In Connecticut, 1,.038 deaths were registered due to the intoxication of a drug. It is for the first time that these deaths have crossed the number of thousand from last five to six years. A large number of the deaths are caused due to consumption of the opioids of the same capacity.
As a support to the addicted people, FDA is working continuously to encourage people to discontinue consumption of opioid, said Dr. Scott Gottlieb, the FDA Commissioner in a news release. He added that opioid addicted people are struggling to remove its addiction as they are afraid of the pain and the other withdrawal symptoms. The fear due to painful withdrawal symptoms is the major reason that the patients are not agreed to change their drugs and treat their addiction.
The withdrawal symptoms include anxiety, agitation, muscle ache, sweating nausea, vomiting, diarrhea and high drug craving. FDA claimed that withdrawal managed by substituting opioid by other medicines. FDA-approved medications including treatment drugs such as buprenorphine, methadone, and naltrexone for the treatment of stomach aches and pains.